Implication of folate deficiency in CYP2U1 loss of function

Area of Science:

• Neuroscience
• Genetics
• Biochemistry

Background:

• Hereditary spastic paraplegias (HSPs) are a group of rare, inherited neurodegenerative disorders.
• The precise pathogenic mechanisms underlying HSPs are not fully understood, and effective treatments are limited.
• Mutations in the CYP2U1 gene are associated with complex forms of HSPs in humans.

Purpose of the Study:

• To characterize a mouse model with a deficiency in the Cyp2u1 gene to understand its role in neurodegeneration.
• To identify potential biomarkers for CYP2U1-related disorders.
• To explore therapeutic interventions for HSPs.

Main Methods:

• Generation and analysis of a Cyp2u1-deficient mouse model.
• Clinical and biochemical phenotyping of the mouse model and patients.
• Electron microscopy, lipidomic, and proteomic analyses.
• Measurement of coenzyme Q, neopterin, and IFN-α levels in mice and human patient samples.
• Investigation of folate supplementation as a potential therapeutic strategy.

Main Results:

• The Cyp2u1-deficient mouse model partially replicated human patient phenotypes.
• Vitamin B2 was identified as a substrate for the CYP2U1 enzyme.
• Coenzyme Q, neopterin, and IFN-α were identified as potential biomarkers in mice and patients.
• Brain calcifications were confirmed as a potential biomarker in patients.
• Folate supplementation showed preventative effects against neurodegeneration in the mouse model.

Conclusions:

• CYP2U1 deficiency disrupts mitochondrial function and negatively impacts neurodevelopment.
• The study identified novel biomarkers for CYP2U1-related disorders.
• Folate supplementation may offer a preventative therapeutic avenue for these conditions.
• Further research into CYP2U1's role is crucial for developing effective HSP treatments.